|
|
 |
|
Total Number of Holdings (excluding cash): 50
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
307,520 |
$87,581,696.00 |
7.71% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
68,168 |
$86,624,486.00 |
7.62% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,770,715 |
$82,705,842.75 |
7.28% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
533,665 |
$79,985,710.20 |
7.04% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
296,622 |
$76,463,219.16 |
6.73% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,388,089 |
$44,060,242.05 |
3.88% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
181,986 |
$43,854,986.28 |
3.86% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
269,416 |
$41,374,215.12 |
3.64% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
511,375 |
$40,715,677.50 |
3.58% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
91,710 |
$40,200,161.40 |
3.54% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
49,345 |
$39,755,786.15 |
3.50% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
68,579 |
$38,643,580.71 |
3.40% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
72,405 |
$37,977,870.60 |
3.34% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
590,136 |
$36,069,112.32 |
3.17% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
316,409 |
$35,893,436.96 |
3.16% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
439,201 |
$28,363,600.58 |
2.50% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
125,353 |
$26,571,075.41 |
2.34% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
91,058 |
$25,756,665.88 |
2.27% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
158,297 |
$19,760,214.51 |
1.74% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
27,163 |
$17,994,944.24 |
1.58% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
38,148 |
$13,156,100.76 |
1.16% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
93,157 |
$13,164,015.67 |
1.16% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
56,473 |
$12,712,072.30 |
1.12% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
230,894 |
$12,747,657.74 |
1.12% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
565,566 |
$12,753,513.30 |
1.12% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
670,799 |
$9,807,081.38 |
0.86% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
39,044 |
$9,597,405.64 |
0.84% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
215,000 |
$6,955,250.00 |
0.61% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
87,757 |
$6,633,551.63 |
0.58% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
239,947 |
$6,473,770.06 |
0.57% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
313,711 |
$6,336,962.20 |
0.56% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
19,286 |
$6,070,847.08 |
0.53% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
39,425 |
$5,879,450.25 |
0.52% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
34,467 |
$5,744,270.22 |
0.51% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
158,203 |
$5,821,870.40 |
0.51% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
61,345 |
$5,702,017.75 |
0.50% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
219,912 |
$5,570,370.96 |
0.49% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
48,351 |
$5,622,254.28 |
0.49% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
100,934 |
$5,369,688.80 |
0.47% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
46,132 |
$5,195,847.16 |
0.46% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
116,625 |
$5,070,855.00 |
0.45% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
37,097 |
$5,122,353.76 |
0.45% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,256 |
$4,915,025.52 |
0.43% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
59,167 |
$4,728,626.64 |
0.42% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
82,678 |
$4,347,209.24 |
0.38% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
51,902 |
$4,053,546.20 |
0.36% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
94,669 |
$3,959,057.58 |
0.35% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
189,561 |
$3,827,236.59 |
0.34% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
66,517 |
$3,913,860.28 |
0.34% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
80,391 |
$3,123,994.26 |
0.27% |
| US Dollar |
$USD |
|
Other |
1,555,020 |
$1,555,020.20 |
0.14% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|